Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.

NCT ID: NCT01793480

Last Updated: 2024-10-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 146 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-01-05
• Study Completion Date: 2014-08-31

Brief Summary

This is a multicentric, randomized, open-label, phase IIIb national study, to evaluate the clinical effects (success/failure) of methadone for the treatment of cancer-related-pain in patients with inadequate pain relief or intolerable side effects when treated with level 3 opioid.

Principal objective is to compare the clinical effects (success/failure) of two methods of methadone titration in patients with cancer-related pain inadequately relieved or with intolerable side effects after treatment with level 3 opioid.

Secondary objectives are : Overall safety of methadone during the study, to describe the patients' characteristics, to describe the effects of methadone on pain relief, to describe the methadone administration, to evaluate patient's quality of life, to evaluate the prescriber's opinion regarding the handling of methadone initiation.

Detailed Description

The randomisation (1:1) will consider the two titration methadone switching methods:

• Group A: patient-controlled dose of methadone with no overlapping with the previous opioid treatment
• Group B: fixed-dose of methadone with overlapping with the previous opioid treatment

Study Description:

Screening visit (Visit 1) within 48 hours before the inclusion Inclusion visit (Visit2) and randomisation on Day 1 Visit 3 from Day 2 to Day 7 (hospitalisation for all patients). Four follow-up visits on Day 14 (Visit 4), Day 21(Visit 5), Day 28 (Visit 6), Day 42 (Visit 7) End of study visit on Day 56 Follow-up phone contact on Day 84.

Conditions

Pain Related to Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

patient-controlled dose of methadone

The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.

Group Type: EXPERIMENTAL

Methadone

Intervention Type: DRUG

fixed-dose of methadone

The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.

Group Type: EXPERIMENTAL

Methadone

Intervention Type: DRUG

Interventions

Methadone

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adult patient of at least 18 years of age
• Patient suffering from cancer disease, undergoing chemotherapy treatment or not, hospitalised or requiring hospitalisation
• Patient presenting nociceptive or mixed pains inadequately relieved with level 3 opioids (morphine, oxycodone, transdermal fentanyl, hydromorphone) with a numeric pain scale score ≥5 evidence-based or presenting intolerable side effects with level 3 opioids
• Patient undergoing level 3 opioid treatment (morphine sulphate or morphine chlorhydrate or fentanyl or oxycodone or hydromorphone)
• Patient presenting a good understanding of the study objectives and able to give his/her written consent
• Patient able to communicate with the investigator or his representative
• Patient available during the whole course of the study and agreeing the study requirements
• Patient with Social Insurance
• Patient having received patient's information form, orally informed and having signed the consent form

Exclusion Criteria

• Patient in terminal cancer disease (life expectancy less than 2 months) according to investigator's judgement
• Patient treated with a medication that may result in an interaction with methadone, such as: antiarrythmic treatments (Ia or III), erythromycin, spiramycin, intravenous vincamin
• Patient receiving opioid treatment for any other reason than pain
• Patient unable to swallow the study treatment
• Patient presenting contra-indication to the use of methadone
• Patient having a decompensated respiratory failure or a severe hepatic disease
• Patient having a known hypersensitivity to methadone
• Patient presenting QT interval prolongation on ECG results
• Patient receiving a concomitant treatment with a morphine-type agonist-antagonist medication (pentazocine, buprenorphine, nalbuphine) or with sultopride, or with morphinic antagonist (naltrexone)
• Patient treated by analgesic radiotherapy within 15 days before inclusion
• Patient participating or having participated in another clinical trial with a new therapy within one month before inclusion
• Patient with a history of substance abuse
• For woman with childbearing potential: pregnancy or breastfeeding.
• Forfeiture of freedom or under guardianship
• Past history of suicidal attempts
• Patient likely not to respect the study conditions and/or study discontinuation criteria according to investigator's judgement
• Patient presenting any other medical condition or illness or clinically significant abnormal findings on the physical examination at screening that, in the opinion of the Investigator, make the patient unsuitable for the study or put the patient at additional risk.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RECORDATI GROUP

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Investigational Site 10

Amiens, , France

Investigational Site 06

Bayonne, , France

Investigational Site 13

Caen, , France

Investigational Site 03

Gap, , France

Investigational Site 11

Le Chesnay, , France

Investigational Site 07

Lille, , France

Investigational Site 16

Lyon, , France

Investigational Site 12

Nice, , France

Investigational Site 14

Paris, , France

Investigational Site 02

Pierre-Bénite, , France

Investigational Site 05

Reims, , France

Investigational site 08

Strasbourg, , France

Investigational Site 17

Suresnes, , France

Investigational Site 01

Tarbes, , France

Investigational Site 04

Toulouse, , France

Investigational Site 15

Villejuif, , France

Countries

France

Other Identifiers

2011-004609-26

Identifier Type: -

Identifier Source: org_study_id